Julie Fitzgerald to Antigens, CD19
This is a "connection" page, showing publications Julie Fitzgerald has written about Antigens, CD19.
Connection Strength
0.231
-
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
Score: 0.196
-
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.
Score: 0.035